Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 16/20 | 0.49 |
| ▸ | CDK1 | P06493 | 9/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.46 |
| ▸ | CDK4 | P11802 | 2/20 | 0.44 |
| ▸ | CCND1 | P24385 | 2/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4495223 | 0.94 | CDK2 (0.54) | CDK2CDK1KCNH2CDK4CCND1 | |
| SCHEMBL4516100 | 0.88 | CDK2 (0.45) | CDK2CDK1KCNH2CDK4CCND1 | |
| SCHEMBL4199394 | 0.82 | CDK2 (0.51) | CDK2CDK1KCNH2CDK4CCND1 | |
| SCHEMBL4495143 | 0.82 | CDK2 (0.60) | CDK2CDK1KCNH2CDK4CCND1 | |
| SCHEMBL4503801 | 0.82 | CDK2 (0.49) | CDK2CDK1CDK4CCND1MAPK8 | |
| SCHEMBL4193060 | 0.80 | CDK2 (0.53) | CDK2CDK1KCNH2CDK4MAPK8 | |
| SCHEMBL3937191 | 0.80 | CDK2 (0.48) | CDK2CDK1CDK4CCND1MAPK8 | |
| SCHEMBL4202924 | 0.80 | CDK2 (0.51) | CDK2CDK1KCNH2CDK4CCND1 | |
| SCHEMBL4515739 | 0.79 | CDK2 (0.61) | CDK2CDK1KCNH2CDK4CCND1 | |
| SCHEMBL4199373 | 0.78 | CDK2 (0.52) | CDK2CDK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| EP-2032559-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007138268-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | CCNI, MKI67, CDK2 | CDK2 3/4885CDK1 22/4885KCNH2 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.